Comparison of INRECSURE and LISA in Preterm Neonates With RDS

Overview

The primary hypothesis of this study is that surfactant administration by INtubate-RECruit-SURfactant-Extubate (IN-REC-SUR-E), via a high frequency oscillatory ventilation recruitment maneuver increases survival without BPD at 36 weeks' gestational age in spontaneously breathing infants born at 24+0-27+6 weeks' gestation affected by Respiratory Distress Syndrome (RDS) and failing nasal CPAP or nasal intermittent positive pressure ventilation (NIPPV) during the first 24 hours of life compared to less invasive surfactant administration (LISA).

BACKGROUND: RDS represents the main cause of respiratory failure in preterm infants and one of the major causes of perinatal morbidity and mortality. Surfactant is a well-established therapy in neonatology, but its optimal administration method remains unresolved, especially with the focus on avoiding MV in preterm infants born before 28 weeks' gestational age (i.e. extremely low gestational age newborns - ELGAN). Duration of MV is a key determinant of the se-verity of bronchopulmo-nary dysplasia (BPD). Although attractive and beneficial in clinical practice, the INtubate, SURfac-tant, Extubate (IN-SUR-E) method cannot be universally applied to all pre-term neonates due to non-homogeneous surfactant distribution and lung derecruitment during intu-bation, resulting in failure rate in preterm infants ranging from 19 % to 69 %. A recent randomized clinical trial showed that the application of a recruitment manoeuvre just before surfactant admin-istration, followed by rapid extubation (INtubate-RECruit-SURfactant-Extubate \[IN-REC-SUR-E\]), decreased the need for MV during the first 72 h of life compared with IN-SUR-E technique in ELGAN, without in-creasing the risk of adverse neonatal outcomes. Recent-ly, a less invasive surfactant administration (LISA) method was developed with surfactant intro-duced into the trachea of infants breathing spontaneously using a small catheter instead of an endo-tracheal tube. The LISA technique poten-tially combines the benefits of early surfactant treatment CPAP avoiding MV. The last network me-ta-analyses on the comparative efficacy of methods for surfactant administration found that among preterm infants, LISA technique was associated with lower likelihood of mortality, need for MV and BPD compared with IN-SUR-E, but these findings did not include comparison to IN-REC-SUR-E method. More importantly, data for ELGAN are not as robust as for the higher gestation age groups. The same Authors of meta-analysis agree that data for ELGAN are not as ro-bust as for higher gestation age group and that lung recruitment before sur-factant administration (IN-REC-SUR-E) represents a promising novel alternative. The investigators therefore de-signed this study to compare the IN-REC-SUR-E technique with LISA for evaluating the compara-tive effectiveness of these techniques in increasing the survival without BPD of ELGANs. METHODS: The primary hypothesis of this study is that IN-REC-SUR-E via a HFOV recruitment maneuver increases survival without BPD at 36 weeks' gestational age in spontaneously breathing ELGAN and failing nCPAP or nasal intermittent positive pressure ventilation (NIPPV) during the first 24 hours of life compared to LISA treatment. Study design: this study is an unblinded multi-center randomized trial of IN-REC-SUR-E vs. LISA in ELGANs. Randomisation and Masking: infants will be allocated to one of the two treatment groups (1:1) ac-cording to a restricted randomization procedure. Stratification factors will include centre and gesta-tional age (24+0 to 25+6 weeks or 26+0 to 27+6 weeks). The table of allocation will not be disclosed to ensure concealment and the randomization will be provided through Research Electron-ic Data Capture (RedCap) web application. The assignment to intervention will be unmasked to all trial par-ticipants: parents, research staff, and medical team will be only aware of study group as-signment af-ter randomization procedures. Management in the Delivery Room: Neonates will be stabilized after birth with positive pressure us-ing a neonatal mask and a T-piece system (i.e. Neopuff Infant Resuscitator ®, Fisher and Paykel, Auckland, New Zealand). All neonates will be started on nCPAP of at least 6 cm H2O via mask or nasal prongs. Newborns who do not breathe or who are persistently bradycardic within the first 60 seconds after birth will receive positive-pressure ventilation with initial FiO2 of 0.30. Infants that will be transitioned successfully to spontaneous breathing will be transferred to NICU on nCPAP (6-7 cm H2O) or NIPPV. The decision to intubate and start MV in the delivery room will be in ac-cordance with the American Heart Association Guidelines. Method and timing of umbilical cord clamping will be as per standard practice at each site. Surfactant treatment Nasal CPAP or NIPPV in the NICU will perform by nasal prongs or nasal mask, with a pressure of 7-8 cm H2O or with a setting of peak inspiratory pressure of 12-15 cmH2O, positive end-expiratory pressure of 7-8 cmH2O and rate of 30-40 breaths/min, respectively. Infants will receive surfactant with IN-REC-SUR-E or LISA if they need a FiO2 ≥ 0.30 maintain a SpO2 between 90% to 94% for at least 30 min. Infants will also be given surfactant if their clinical status will deteriorate rapidly or will develop respiratory acidosis defined as a pCO2 more than 65 mmHg (8.5 kPa) and a pH less than 7.20, or with lung ultrasound scoring \>8. A loading dose of intravenous caffeine citrate (20 mg/kg) will be given in the delivery room or immediately after admission to the NICU (within 2 hours of life) or in any case prior to surfactant administration, followed by a daily morning in-trave-nous dose of 5-10 mg/kg as required. All neonates of both groups will receive preprocedural medications using intravenous atropine (10 µg/kg) in one minute followed by intravenous fentanyl: 0.5 µg/kg by pump infusion in no less than 5 minutes (possibly repeatable dose if satisfactory analgosedation is not obtained) or followed by in-travenous ketamine: 0.5 mg/kg in no less than one minute (possibly repeatable dose if satisfactory analgosedation is not obtained). Method of premedication will be documented in each participating centre. IN-REC-SUR-E group infants after intubation, will receive HFOV starting at MAP 8 cmH2O; fre-quency 15 Hz, with volum guarantee (1.5-1.7 mL/kg). The I:E will be 1:1. An oxygenation guided lung recruitment procedure will be performed using stepwise increments then decrements in MAP. The starting MAP will be increased stepwise as long as SpO2 improves reducing the FiO2 keeping SpO2 within the target range (90-94 %) until the oxygenation no longer improves or the FiO2 is equal to or less than 0.25 (opening MAP). Next, the MAP will be reduced stepwise until the SpO2 deteriorates (closing MAP). After a second recruitment maneuver at the opening pressure, the opti-mal MAP will be set 2 cmH2O above the closing MAP. Then 200 mg/kg of poractant alfa (Chiesi Farmaceutici S.p.A., Parma, Italy) via a closed administration system will administrate. In-fants with sufficient respiratory drive will be extubated within 30 minutes after surfactant admin-istration start-ing nCPAP (7-9 cm H2O) or NIPPV. LISA Group infants allocated will receive 200 mg/kg of poractant alfa (Chiesi Farmaceutici S.p.A., Parma, Italy) during nCPAP of 7-8 cmH2O. Surfactant will be administered over 0.5-3 min using the SurfCath™ tracheal instillation catheter (VYGON S.A. - Ecouen, France), or a 4- 6 F end-hole catheter. The infant's mouth will be closed. In cases of apnoea or bradycardia, positive pressure ven-tilation will be performed until recovery. After surfactant administration, CPAP (7-9 cm H2O) or NIPPV will be continued. Transcutaneous PaCO2 will be recorded during surfactant administration in both the procedures (IN-REC-SUR-E and LISA), if available. In nCPAP infants, the decision as to whether to begin bilevel positive airway pressure or NIPPV to prevent the need for re-intubation in infants of both groups will be up to the neonatologist on duty and will be considered in the final analysis. Infants in both groups who meet the CPAP/NIPPV fail-ure criteria again during the following 24 h will receive a second dose of surfactant (100 mg/kg of poractant alfa) according to the randomized group (IN-REC-SUR-E or LISA). The indications for MV after IN-REC-SUR-E or LISA will be: Poor oxygenation with FiO2 of greater than 0.40 to maintain a SpO2 between 90% to 94% despite CPAP (7-9 cm H2O) or NIPPV; respiratory; apnoea, despite optimal noninvasive respiratory sup-port. Primary outcome is a composite outcome of death or BPD at 36 weeks' postmenstrual age. DATA COLLECTION AND MANAGMENT. A customized eCRF (eletronic Case Report Form) will be created for the study. Pseudo-anonimyzed study data will be collected and managed using REDCap electronic data capture tools hosted at Fondazione Policlinico Universitario A. Gemellli, IRCCS (https://redcap-irccs.policlinicogemelli.it/). All collected data will be obtained from the clini-cal records. All data above listed in "Primary out-come measure", "secondary outcome measure", and "Other collected data" sections. Adverse events, device deficiency and incidents will be rec-orded and reported to Manufacturer and the National Competent Authority as per applicable law. Statistical analysis The investigators hypothesized that IN-REC-SUR-E technique for surfactant administration might increase the survival without BPD at 36 weeks of postmenstrual age in extremely preterm infants, respect to LISA approach, from 65 % to 80 %. The investigators based the 15 % difference estimate from the data of the German Neonatal Network (GNN) on the LISA approach, from the results of the OPTIMIST trial recently published and from updated data on the IN-REC-SUR-E technique of some Italian Centers that continued to use this strategy even after that the INRECSURE study had ended. The investigators calculated that 181 newborns must be enrolled in each group to detect this difference as statistically significant with 90 % power at 0.05 level. 381 patients will be randomly assigned to accommodate the risk of enrolling a 5% of patients judged not meeting inclusion criteria after randomization. Twins will be separately randomized. Analyses will be done according to the intention-to-treat and per-protocol principles, as suggested by CONSORT guidelines, with the primary outcome assessed in the in-ten-tion-to-treat population. The intention-to-treat population will include all participants assigned to study intervention, and the per-protocol population will include all participants who receive and complete the study intervention, and who met study criteria. For the primary outcome, a log-binomial regression model correcting for the stratification factors of gestational age and study centre will be used to estimate the adjusted relative risk (RR). Moreover, the absolute risk reduction and the number-needed-to-treat will be calculated. Statistical analyses will be done using Stata software, version 16. An interim-analysis for safety to evaluate the prespecified stopping rules will be done at 30 % of recruitment by an independent statistician, masked to the treatment allocation. The prespecified clinical and safety outcomes will be: in-hospital mortality, intraventricular haemor-rhage worse than grade 2 and pneumothorax. The data and safety monitoring board will have un-masked access to all data and will discuss the results of the interim analysis with the steer-ing com-mittee in a joint meeting. The steering committee will decide on the continuation of the trial and will report to the central ethics committee. Duration of study: 3 years QUALITY CONTROL AND QUALITY ASSURANCE PROCEDURES Compliance to protocol Compliance will be defined as full adherence to protocol. Compliance with the protocol will be ensured by a number of procedures as: site set-up local principal investigators are required to participate in preparatory meetings in which details of study protocol, data collection, "IN-REC-SUR-E" and "LISA" procedures will be accurately discussed. All centers will receive de-tailed written instruction on web based data recording, and, to solve possible difficulties, it will be possible to contact the Clinical Trials Coordinating Center. Moreover, it has been ascertained that "IN-REC-SUR-E" and "LISA" procedures are followed similarly in all participating centers.